{"transactions":[{"id":4616503,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T23:51:38.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":117,"price":1.18,"value":138.06,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001193125-26-389550","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526389550/ownership.xml","form_type":"4"}},{"id":4616502,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T23:51:38.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":19883,"price":1.17,"value":23263.11,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":19883,"source":{"system":"sec-edgar","filing":"0001193125-26-389550","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526389550/ownership.xml","form_type":"4"}},{"id":741660,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:30:21.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock (\"Company Option\") that was outstanding and unexercised immediately prior to the effective time of the Merger (the \"Effective Time\") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.07,"expiration_date":"2034-11-24","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001492749-26-000002","document":"form4-06112026_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000149274926000002/form4-06112026_080604.xml","form_type":"4"}},{"id":741659,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T18:31:48.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":17400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":17400,"derivative":{"exercise_price":1.23,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":17400},"source":{"system":"sec-edgar","filing":"0001193125-26-267272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000119312526267272/ownership.xml","form_type":"4"}},{"id":1051408,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-02T20:44:51.000Z","date":"2025-09-02","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares subject to this option shall vest and become exercisable on September 2, 2026, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":42000,"derivative":{"exercise_price":1.82,"expiration_date":"2035-09-01","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0000950170-25-112535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000095017025112535/ownership.xml","form_type":"4"}},{"id":1350878,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-26T21:41:52.000Z","date":"2024-11-23","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":17000,"derivative":{"exercise_price":10.07,"expiration_date":"2034-11-22","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001415889-24-027736","document":"form4-11262024_091149.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000141588924027736/form4-11262024_091149.xml","form_type":"4"}},{"id":1773906,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-25T20:25:59.000Z","date":"2023-09-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1072539,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a \"Tranche 2 Option\") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a \"Tranche 2 Option\") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR."}],"balance_after":0,"derivative":{"exercise_price":4.4,"expiration_date":"2030-12-07","underlying":"Common Stock","underlying_shares":1072539},"source":{"system":"sec-edgar","filing":"0000899243-23-019490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924323019490/doc4.xml","form_type":"4"}},{"id":1773905,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-25T20:25:59.000Z","date":"2023-09-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a \"Tranche 1 Option\"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a \"Tranche 1 Option\"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.73,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0000899243-23-019490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924323019490/doc4.xml","form_type":"4"}},{"id":1773904,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-25T20:25:59.000Z","date":"2023-09-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":187500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a \"Tranche 1 Option\"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a \"Tranche 1 Option\"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2032-02-24","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000899243-23-019490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924323019490/doc4.xml","form_type":"4"}},{"id":1773903,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-09-25T20:25:59.000Z","date":"2023-09-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":220849,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. (\"Parent\") and Symphony Acquisition Sub, Inc. (\"Purchaser\"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer held by the reporting person were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the \"Cash Consideration\"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a \"CVR\"),"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the \"CVR Agreement\"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer  (each a \"Company RSU\"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 195,000 unvested Company RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. (\"Parent\") and Symphony Acquisition Sub, Inc. (\"Purchaser\"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer held by the reporting person were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the \"Cash Consideration\"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the \"CVR Agreement\"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer  (each a \"Company RSU\"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019490","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924323019490/doc4.xml","form_type":"4"}},{"id":1946921,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Options (right to buy)","published_at":"2023-03-17T20:24:32.000Z","date":"2023-03-16","kind":"grant","acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on March 16, 2023. The shares underlying the option are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025."}],"balance_after":72000,"derivative":{"exercise_price":3.73,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0000899243-23-008873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924323008873/doc4.xml","form_type":"4"}},{"id":1946920,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-17T20:24:32.000Z","date":"2023-03-16","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of the Issuer's common stock issuable under 195,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest with respect to 40% of the shares on January 26, 2024, and with respect to the remainder on January 26, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 195,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting."}],"balance_after":220849,"source":{"system":"sec-edgar","filing":"0000899243-23-008873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924323008873/doc4.xml","form_type":"4"}},{"id":2368972,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Options (right to buy)","published_at":"2022-02-28T21:36:36.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026."}],"balance_after":187500,"derivative":{"exercise_price":3.5,"expiration_date":"2032-02-24","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000899243-22-008086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924322008086/doc4.xml","form_type":"4"}},{"id":2565727,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":39261,"kind":"person","name":"Reid Laurence","position":1,"cik":"0001492749","reported_name":"Reid Laurence","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Chief Executive"}}],"security":"Common Stock","published_at":"2021-09-18T01:48:07.000Z","date":"2021-09-15","kind":"purchase","acquired":true,"shares":10000,"price":7.64,"value":76400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.587 to $7.65, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price."}],"balance_after":25849,"source":{"system":"sec-edgar","filing":"0000899243-21-036500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492749/000089924321036500/doc4.xml","form_type":"4"}}]}